Please login to the form below

Not currently logged in
Email:
Password:

Plendil

This page shows the latest Plendil news and features for those working in and with pharma, biotech and healthcare.

AZ adds gout drug Zurampic to asset sale

AZ adds gout drug Zurampic to asset sale

Last month, AZ sold European rights to its opioid-induced constipation treatment Moventig (naloxegol) to ProStrakan and transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur (isosorbide mononitrate) -

Latest news

  • AZ offloads more products in slimming drive AZ offloads more products in slimming drive

    AZ offloads more products in slimming drive. Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline. ... Meanwhile, earlier this week AZ also transferred Chinese rights to two elderly cardiovascular drugs - Plendil (felodipine) and Imdur

  • Update on AZ-Merck deal

    AZ will purchase rights to several Merck products, including the Crohn's Disease treatment Entocort, and blood pressure dugs Atacand, Lexxel and Plendil.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    $223m royalties. $142m. 1.6. Cardiovascular 2016. China Medical System. Plendil China.

  • Deal Watch February 2016 Deal Watch February 2016

    Being particularly active in out-licensing, AstraZeneca has granted a licence to China Medical System (CMS) in return for $310m to sell Plendil (felodipine), a calcium antagonist for hypertension in China. ... collaboration expanded. 500. AstraZeneca/

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics